hOCT1 Gene Expression Might Predict Molecular Response In Patients with Chronic Myeloid Leukemia

Autor: Silvia Marcé, Marta Cabezón, Cristalina Fernandez, Javier Grau, Diana Marcela Ruíz Domínguez, Blanca Xicoy, Josep-Maria Ribera, David Gallardo, Alberto Fernández de Sevilla, Jordi Ribera, Fuensanta Millá, Isabel Granada, Concha Boqué, Lurdes Zamora, Evarist Feliu
Rok vydání: 2010
Předmět:
Zdroj: Blood. 116:4838-4838
ISSN: 1528-0020
0006-4971
DOI: 10.1182/blood.v116.21.4838.4838
Popis: Abstract 4838 Introduction: Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of BCR/ABL fusion gene. The resulting protein has a high tyrosine kinase (TK) activity. The first-line treatment for CML is Imatinib, which allow the achievement of cytogenetic and molecular response in most of patients with CML in chronic phase. However, some patients do not respond to this treatment or lose their initial response. Imatinib has been reported to be incorporated into the cell through hOCT1 transporter (human organic cation transporter). The aim of this study was to determine whether the expression of hOCT1 at diagnosis of CML influenced the achievement of molecular response. Patients and Methods: We analyzed hOCT1 gene expression by quantitative PCR in 42 patients at diagnosis and 18 months after treatment with Imatinib. We compared the expression with the presence of compleat molecular response (CMR) at 18 months. We consider CMR when the Ratio (BCR-ABL/ABL)×100 was Results: Of the 42 patients, 2 were in hematological response, 22 were in cytogenetic response and 18 in CMR at 18 months. We found a higher hOCT1 gene expression at 18 month than at diagnosis (53.3 versus 29.6, p Conclusions: Partially funded by FICJ-P-EF-09, RD06/0020/1056 de RTICC and Novartis. We want to thank Dr. David Marin for providing us plasmid for quantitative analysis. Disclosures: No relevant conflicts of interest to declare.
Databáze: OpenAIRE
Externí odkaz: